Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study

Jonathan Q. Trinh, Ying Xiong, Lynette M. Smith, Omar Abughanimeh, Alissa S. Marr, Apar K. Ganti

Research output: Contribution to journalArticlepeer-review


Background/Aim: The PACIFIC trial demonstrated improved survival in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with durvalumab following definitive concurrent chemoradiotherapy (CRT). This study sought to explore real-world outcomes with durvalumab consolidation therapy at our institution. Patients and Methods: We retrospectively identified patients diagnosed with stage III NSCLC at our institution from January 2012 to January 2022. We created two cohorts: one who received durvalumab following definitive CRT and a historical one who did not. Primary outcomes of interest included median progression-free survival (PFS) and overall survival (OS). Additionally, we performed subgroup analysis on the durvalumab cohort to explore the associations between survival and time to durvalumab initiation, PD-L1 expression, and neutrophil-to-lymphocyte ratio (NLR). Results: We identified 79 patients with locally advanced NSCLC who were not surgical candidates. Patients treated with durvalumab (n=44) had significantly improved survival compared to the historical cohort (n=35) including a median PFS of 17.4 months versus 8.0 months (p=0.0019) and a median OS of 37.0 months versus 17.0 months (log-rank p-value=0.07, Wilcoxon p-value=0.02).

Original languageEnglish (US)
Pages (from-to)605-612
Number of pages8
JournalAnticancer Research
Issue number2
StatePublished - Feb 2024


  • PD-L1
  • Stage III non-small cell lung cancer
  • durvalumab
  • immunotherapy
  • neutrophil-to-lymphocyte ratio

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study'. Together they form a unique fingerprint.

Cite this